Clinical trial NCT06383702: A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Pregabalin Sustained-Release Tablets for the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Painful Diabetic Neuropathy
Lead sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-04-25
Enrollment: 358
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel design
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the efficacy and safety of pregabalin extended-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Pregabalin has been approved in more than 130 countries for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and neuralgia associated with spinal cord injury. Pregabalin extended-release tablets were administered once daily, as a single dose after dinner. Compared with pregabalin capsule formulation, it reduces the frequency of medication and improves patient compliance.

Detailed description: This is a multicenter, randomized, double-blind, placebo-controlled trial, the study was designed to evaluate the efficacy and safety of pregabalin sustained-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. The study includes a screening period (3 weeks, including baseline/run-in period), a treatment period (titration period, fixed dose period and withdrawal period), and a follow-up period. During the treatment period participants will receive pregabalin sustained-release tablets/placebo as daily treatment.

Eligibility criteria: Inclusion Criteria:

* Aged ≥ 18 years and ≤ 75 years at screening;
* diagnosed with type 1 or type 2 diabetes for ≥ 1 year;
* diagnosed with distal symmetrical polyneuropathy caused by diabetes (type 1 or type 2), with duration of neuropathic pain associated with diabetic peripheral neuropathy ≥ 6 months;
* clearly understood and voluntarily participated in the study, and signed the informed consent form by themselves.

Exclusion Criteria:

* Subjects with other conditions that may confound the assessment of Neuropathic Pain associated with Diabetic Peripheral neuropathy (DPNP), such as: neuropathic pain other than DPNP (cervical spondylosis, carpal tunnel syndrome, spinal stenosis, postherpetic pain, etc.), pain caused by other causes (gout, chronic obstructive arteriosclerosis, arthritis, etc.), and other pain at the assessment site (skin diseases and trauma);
* subjects with known or suspected allergic reactions to various components of pregabalin sustained-release tablets or compounds closely related to paracetamol or paracetamol;
* subjects with clinically significant or unstable diseases, such as but not limited to severe cardiovascular disease, cerebrovascular disease, liver, kidney, respiratory system, blood system, immune system diseases, inflammatory or rheumatic diseases, uncontrolled infection, untreated endocrine diseases, etc., and other conditions that judged by the investigator to influence participation in the trial;
* subjects who have undergone renal transplantation, or are undergoing renal dialysis;
* subjects with uncontrolled narrow-angle glaucoma, uncontrolled seizure history, or uncontrolled or poorly controlled hypertension;
* Pregnant or lactating females or subjects planning to father a child during the trial (including males);
* subjects with a history of drug or alcohol abuse within one year prior to screening; patients who, in the opinion of the investigator, are not suitable for participation in this trial.

Primary outcomes:
measure: Numeric Rating Scale (NRS) mean change at week 13.
timeFrame: Week 13
Secondary outcomes:
measure: NRS mean change at Weeks 1-12 and 14
timeFrame: Weeks 1-12 and 14
measure: Proportion of subjects with NRS change
timeFrame: Week 13
measure: Brief McGill Pain Questionnaire (SF-MPQ) score
timeFrame: Weeks 1, 5, 9, 13, and 14
measure: Medical Outcomes Study Sleep Scale (MOS-SS) score
timeFrame: Weeks 1, 5, 9, 13, and 14
measure: Hospital Anxiety and Depression Scale (HADS) score
timeFrame: Weeks 1, 5, 9, 13, and 14
measure: Patient Global Impression of Improvement (PGIC) score
timeFrame: Weeks 1, 5, 9, 13, and 14
measure: Clinical Global Impression of Improvement (CGIC) score
timeFrame: Weeks 1, 5, 9, 13, and 14
Other outcomes:
Locations:
Study officials:
References: